27 September 2021 - Enfortumab vedotin is the first and only antibody-drug conjugate approved in Japan for patients with advanced urothelial cancer -

Astellas Pharma and Seagen today announced that Japan's Ministry of Health, Labour and Welfare has approved Padcev (enfortumab vedotin) for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. 

The new drug application received priority review.

Read Astellas press release